Please assess the completion status of the following clinical trial:

Trial Title: Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to comply with study protocols~* Willing to drink 2 tablespoons of olive oil~* BMI 18.5 to 30 kg/m2~* Weight ≥ 110 pounds~Exclusion Criteria:~* Adults who are not able to consent~* BMI ≥ 31 kg/m2~* Under current medical supervision~* Self-reported daily use of drugs that are known to affect platelet function, such as aspirin, Excedrin, and NSAIDS~* Ibuprofen intolerance or allergy~* Cannot speak English~* Allergy to olives or olive oil~* Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or individual following diets with significant deviations from the average diet of the general population.~* A history of cardiovascular disease, stroke, cancer, renal, hepatic, or thyroid disease, GI tract disorders, previous GI surgery~* Currently taking prescription drugs or supplements~* Indications of substance or alcohol abuse within the last 3 years~* Not willing to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements.~* Not willing to refrain from olive oil consumption.~* Blood Pressure ≥ 140/90 mmHg~* Self-reported malabsorption~* Metabolic panel results or complete blood counts that are outside of the normal reference range.~* Screening LDL ≥ 190 mg/dl for those who have 0 - 1 major risk factors apart from LDL cholesterol \[(i.e. family history of premature coronary artery disease (male first degree relative \< 55 years; CHD in female first degree relative \< 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL\].~* Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL cholesterol \[(i.e. family history of premature coronary artery disease (male first degree relative \< 55 years; CHD in female first degree relative \< 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL\].~* Screening LDL ≥ than 130 mg/dl for those who have 2 major risk factors apart from LDL cholesterol ((i.e. family history of premature coronary artery disease (male first degree relative \< 55 years; CHD in female first degree relative \< 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL), and a Framingham 10 - year Risk Score 10 - 20 % (using NCEP calculator).~* Current enrollee in a clinical research study.~* Individuals with blood clotting or platelet defect disorders

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Oleocanthal-rich, D2i2 (Type: EXPERIMENTAL): Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
- Oleacein-rich, D2i0.5 (Type: EXPERIMENTAL): Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
- Oleocanthal and Oleacein-low, D2i0 (Type: PLACEBO_COMPARATOR): Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
- Ibuprofen (Type: ACTIVE_COMPARATOR): Ibuprofen, 400 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete